NCT07081997View on ClinicalTrials.gov

A Phase 3 Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
HypoparathyroidismEndocrine System DiseasesParathyroid Diseases
Interventions
COMBINATION_PRODUCT

Palopegteriparatide

Palopegteriparatide is supplied as a solution with a concentration of 0.3 mg/mL in a single-patient-use prefilled pen intended for subcutaneous injection.

All Listed Sponsors
lead

Ascendis Pharma Bone Diseases A/S

INDUSTRY